Regular physical activity may protect against cognitive decline as we get older, but this protective effect may be diminished for people who are not getting enough sleep, according to a new study by UCL researchers.
Older people who have fluctuating levels of cholesterol and triglycerides may have a higher risk of Alzheimer’s disease and related dementias compared to people who have steady levels, according to new research published in the July 5, 2023, online issue of Neurology®, the medical journal of the American Academy of Neurology. While the study found a link, it does not prove that fluctuating levels of cholesterol and triglycerides cause dementia.
Taking good care of your teeth may be linked to better brain health, according to a study published in the July 5, 2023, online issue of Neurology®, the medical journal of the American Academy of Neurology. The study found that gum disease and tooth loss were linked to brain shrinkage in the hippocampus, which plays a role in memory and Alzheimer’s disease. The study does not prove that gum disease or tooth loss causes Alzheimer’s disease; it only shows an association.
Older adults with Alzheimer disease and related dementia who were admitted to an ICU were much less likely to be discharged home and faced almost twice the risk of dying soon after discharge and within the 12 months afterward.
Protein aggregates accumulate during aging and are linked to neurodegenerative diseases like Alzheimer’s, Parkinson’s or Huntington’s disease.
Cedars-Sinai patient care teams are preparing to offer lecanemab, a new Alzheimer’s disease treatment expected to soon receive approval from the U.S. Food and Drug Administration (FDA), to patients in the coming months.
Mild cognitive impairment, which occurs in about one in six individuals in the U.S., age 65 and older, remains substantially underdiagnosed, especially in disadvantaged populations.
The June 2023 issue of SLAS Discovery contains one review article, five full-length articles and two technical briefs covering spheroid models, 3D cell high-throughput screening (HTS) applications for treating Alzheimer’s and other drug discovery research.
A new AI tool that could help doctors assess the early signs of dementia and Alzheimer’s more quickly and efficiently, has been developed by researchers at the University of Sheffield.
Dogs who slow down physically also slow down mentally, according to a new study from North Carolina State University. Measuring gait speed in senior dogs could be a simple way to monitor their health and to document decline in their neurological function as they age.
In a study that followed more than 2,000 community-dwelling older adults over eight years, researchers at Johns Hopkins Medicine say they have significant new evidence of a link between decreased sense of smell and risk of developing late-life depression.
Women with atrial fibrillation progress more rapidly to cognitive impairment and dementia than men with the heart rhythm condition, according to research presented today at ACNAP 2023, a scientific congress of the European Society of Cardiology (ESC)1 and published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association.
Alzheimer's disease (AD) mainly affects the older population. Recent research found early disease signs in cell culture models of early human brain development, raising the possibility that the disease has its origins much earlier in life, possibly during embryogenesis – the formation and development of an embryo.
In an eight-year study of more than 600 community-dwelling older adults, Johns Hopkins Medicine researchers say they have further linked levels of cell-free DNA (DNA fragments resulting from cell death) circulating in the blood to chronic inflammation and frailty.
Today, Veravas, a leading innovator in clinical diagnostics, announced the launch of its groundbreaking VeraBIND™ (Biomarker Isolation and N-richment for Detection) technology
Adults who live in walkable neighborhoods are more likely to socialize and have a stronger sense of community, report researchers at the UC San Diego Herbert Wertheim School of Public Health and Human Longevity Science.
New research from Boston Medical Center found a significant correlation between biomarkers in the vitreous humor of the eye and pathologically confirmed cases of Alzheimer’s disease (AD) and Chronic Traumatic Encephalopathy (CTE) in post-mortem brain and eye tissue.
Scientists at City of Hope have developed universal donor stem cells that could one day provide lifesaving therapy to children with lethal brain conditions, such as Canavan disease, as well as to people with other degenerative diseases, such as Alzheimer’s and multiple sclerosis.
The University of California, Irvine has received a five-year, $10 million grant from the National Institutes of Health to lead a multi-institutional study of specific brain cell vulnerabilities to abnormal tau protein deposits in regions affected in the early stages of Alzheimer’s disease.
Alzheimer’s disease causes changes to the brain that begin two decades or more before symptoms appear. A study by researchers at Washington University School of Medicine in St. Louis reveals that the bacteria that live in the gut also change before Alzheimer’s symptoms arise, a discovery that could lead to diagnostics or treatments for Alzheimer’s disease that target the gut microbiome.
A new approach could enhance memory and learning in individuals with Down syndrome by stabilizing a key component in the body's protein sorting system called the retromer complex.
The American Academy of Neurology (AAN), the world’s largest association of neurologists and neuroscience professionals, has submitted a Formal National Coverage Determination (NCD) Reconsideration Request to the Centers for Medicare & Medicaid Services (CMS) regarding the existing national coverage determination on Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease, including the new therapy lecanemab.
Researchers from The University of Texas at El Paso’s School of Pharmacy will explore the viability of a new treatment for vascular dementia, thanks to a $2.2 million grant from the National Institutes of Health National Institute of Neurological Disorders and Stroke.
Matthew Lew, an associate professor of electrical and systems engineering at the McKelvey School of Engineering at Washington University in St. Louis, has received a five-year $2 million Maximizing Investigators’ Research Award (MIRA) from the National Institutes of Health (NIH) to support his ongoing work to improve microscopic imaging techniques.
A research consortium, including a Philadelphia College of Osteopathic Medicine neuroscientist and his research coordinator, are calling for a consensus on how scientists identify and evaluate how infections contribute to or cause cognitive impairment and dementias, including Alzheimer’s disease.
Pitt unveils National Sports Brain Bank to track patients with contact-sports backgrounds; Steelers legends Jerome Bettis, Merril Hoge pledge brains and participation in innovative program.
The quality of care for nursing home residents with Alzheimer’s disease and related dementias is best when they are in the majority, but most facilities also accommodate a heterogeneous population, where specialized staff training is limited, according to a study led by the University of California, Irvine.
Sleep medicine experts from the Mount Sinai Health System are presenting new research at SLEEP 2023, the 37th annual meeting of the Associated Professional Sleep Societies running until June 7 in Indianapolis.
A roundup of the latest medical discoveries and faculty news at Cedars-Sinai in May 2023.
This study provides provides the first physiological evidence from inside the human brain supporting the dominant scientific theory on how the brain consolidates memory during sleep. Further, deep-brain stimulation during a critical time in the sleep cycle appeared to improve memory consolidation.
Experts available on the correlation between binge watching television and dementia later in life
Studies have shown that sleep apnea is related to an increased risk of dementia. A new study looks at the relationship between sleep apnea and brain volume. The study is published in the May 31, 2023, online issue of Neurology®, the medical journal of the American Academy of Neurology.
A biomarker is a characteristic that can be measured and evaluated as an indicator of normal biological processes, pathogenetic processes, or pharmacologic responses to a therapeutic intervention. In the context of Alzheimer’s disease (AD), an AD biomarker indicates the presence or progression of the disease that may be altered by drug treatment, thereby demonstrating that it is hitting its target. Today, all clinical trials for Alzheimer’s disease utilize biomarkers of some form to assess whether the drug is actually affecting the disease in the brain.
The Lewis Katz School of Medicine created the Alzheimer’s Center at Temple from funds donated by Board of Trustees member Phil Richards earlier this month. Richards’s gift created the center and established the Scott Richards North Star Charitable Foundation Chair for Alzheimer’s Research.
Did you know that music might be able to connect you with your family members affected by Alzheimer's disease (AD) in a way that words cannot? Many studies have shown that music can evoke a response or a memory in people with Alzheimer's Disease.
The risk of side effects can rise if drugs are taken for conditions other than Alzheimer's disease (AD) treatment. Some sedatives and antidepressants can deteriorate cognitive function, make people drowsy and confused, and worsen cognitive impairment, which increases the risk of falls.
Alzheimer-like changes – marked by the build-up of harmful amyloid and tau proteins – occur in the brain in Down syndrome has been unclear. But now, in new research, scientists at the Lewis Katz School of Medicine at Temple University show that reduced efficiency of a key protein transport system is partly to blame.
Diagnosing Alzheimer's disease (AD) is a complex process that doesn't rely on a single test.
Alzheimer's disease is the most common form of dementia in the elderly. Memory loss and difficulty thinking worsen progressively, with some patients eventually becoming delusional, disoriented, and vulnerable to mood swings and depression. Finding ways to slow or reverse this progression, or even prevent symptoms from developing in the first place, are major goals in Alzheimer's research.
People may endure cognitive changes as they get older, including forgetfulness and a loss of their capacity for multitasking or concentration. Although these changes are typical, they can be upsetting for elderly people.
Alzheimer's disease is a debilitating condition that affects millions of people around the world, but there is also a lot of misinformation about it. One of the most common myths is that memory loss is a natural part of aging.
According to the newly released “Alzheimer’s Disease Drug Development Pipeline: 2023,” there are currently 187 clinical trials in the Alzheimer’s drug development pipeline – the most ever on record. This momentum is driven in part by greater investment from the pharma industry and a bump in biologic therapies – particularly monoclonal antibodies – that were central to the success of both recent FDA-approved drugs. The annual report spots trends in clinical trial design and outcome measures, and also investigate the types of agents and biological targets that are being pursued.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
